TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30452209

Group type: EXPERIMENTAL
Intervention: Extended-release injectable naltrexone (XR-NTX)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Buprenorphine-naloxone (BUP-NX)
Number of subjects: 0
Study: 26888075

Group type: EXPERIMENTAL
Intervention: Tafenoquine (TQ)
Number of subjects: 198

Group type: COMPARATOR
Intervention: Primaquine (PQ)
Number of subjects: 198
Study: 24211507

Group type: EXPERIMENTAL
Intervention: Bioabsorbable polymer-based biolimus-eluting stents (BP-BES)
Number of subjects: 85490
Study: 22159173

Group type: EXPERIMENTAL
Intervention: Autorefraction (AR‐EVA score)
Number of subjects: 456

Group type: COMPARATOR
Intervention: Manual refraction (MR‐EVA score)
Number of subjects: 456
Study: 21180000

Group type: EXPERIMENTAL
Intervention: Chlorhexidine (CHX) + rinsing + etching
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Chlorhexidine (CHX) + no rinsing + etching
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Etching + Chlorhexidine (CHX) + rinsing
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Etching + Chlorhexidine (CHX) + no rinsing
Number of subjects: 50

Group type: COMPARATOR
Intervention: Etching only (Control group)
Number of subjects: 50
Study: 19015420

Group type: EXPERIMENTAL
Intervention: Indigo naturalis ointment
Number of subjects: 42

Group type: COMPARATOR
Intervention: Vehicle ointment
Number of subjects: 42
Study: 15785911

Group type: EXPERIMENTAL
Intervention: Laser in situ keratomileusis (LASIK)
Number of subjects: 25
Study: 11858973

Group type: EXPERIMENTAL
Intervention: Phase II and phase III trials for patients with acute and chronic myeloid or lymphoid leukaemia, myelodysplastic syndromes and myeloma
Number of subjects: 330
Study: 10711101

Group type: EXPERIMENTAL
Intervention: Regular daily telephone call reminders
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Daily videotelephone call reminders
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group (usual care)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: All groups (including both intervention groups)
Number of subjects: 34
Study: 7477807

Group type: EXPERIMENTAL
Intervention: Vitamin supplementation (10 times the recommended daily dose of 9 vitamins)
Number of subjects: 129

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 129
Study: 2029816

Group type: EXPERIMENTAL
Intervention: Tympanic membrane temperatures taken with Thermoscan
Number of subjects: 137
Study: 7280486

Group type: EXPERIMENTAL
Intervention: Intra-articular hydrocortisone
Number of subjects: 12

Group type: COMPARATOR
Intervention: Intra-articular saline (control)
Number of subjects: 12
Study: 30053521

Group type: EXPERIMENTAL
Intervention: Prototype LSS belt
Number of subjects: 104

Group type: COMPARATOR
Intervention: Lumbar support
Number of subjects: 104
Study: 29885166

Group type: EXPERIMENTAL
Intervention: Onlay technique (Group A)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Sublay technique (Group B)
Number of subjects: 100
Study: 25727335

Group type: EXPERIMENTAL
Intervention: Mouthrinse containing 0.05% chlorhexidine, 0.05% cetylpyridinium chloride and 0.14% zinc lactate (CHX‐CPC‐Zn)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Mouthrinse containing 0.05% chlorhexidine, 0.15% triclosan and 0.18% zinc pidolate (CHX‐triclosan‐Zn)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Saline solution (NaCl 0.9%)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Mechanical plaque control (MPC)
Number of subjects: 11
Study: 24945948

Group type: EXPERIMENTAL
Intervention: Bupivacaine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 0
Study: 23136958

Group type: EXPERIMENTAL
Intervention: Intervention arm (n=18) received a narrative in ChiChewa with a power point presentation and discussions.
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control arm (n=18) received standard informed consent information for the microbicide trial.
Number of subjects: 36
Study: 20482476

Group type: EXPERIMENTAL
Intervention: Treadmill walking with body weight support
Number of subjects: 126

Group type: COMPARATOR
Intervention: Overground walking
Number of subjects: 126
Study: 18926156

Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stents (XIENCE V Everolimus-Eluting Coronary Stent System)
Number of subjects: 39
Study: 16977642

Group type: EXPERIMENTAL
Intervention: Guided imagery with relaxation (GIR) for 12 weeks
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control intervention
Number of subjects: 28
Study: 12697580

Group type: EXPERIMENTAL
Intervention: Arizona Food Frequency Questionnaire (AFFQ)
Number of subjects: 397

Group type: EXPERIMENTAL
Intervention: 24‐hour dietary recalls
Number of subjects: 397

Group type: COMPARATOR
Intervention: Comparison group (control)
Number of subjects: 397
Study: 10224846

Group type: EXPERIMENTAL
Intervention: Interferon-beta-1b
Number of subjects: 35
Study: 8724065

Group type: EXPERIMENTAL
Intervention: Pneumococcal glycoprotein conjugate vaccine (primary immunization)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Pneumococcal polysaccharide vaccine (secondary immunization)
Number of subjects: 60
Study: 1929247

Group type: EXPERIMENTAL
Intervention: Amoxicillin-clavulanate, 1 g plus 250 mg per os every 12 h for 3 days
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Amoxicillin-clavulanate, 1 g plus 250 mg per os every 12 h on day 3 only (1-day regimen)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 6191130

Group type: EXPERIMENTAL
Intervention: Indoramin
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 29260952

Group type: EXPERIMENTAL
Intervention: Difluprednate 0.05%
Number of subjects: 0

Group type: COMPARATOR
Intervention: Prednisolone Acetate 1%
Number of subjects: 0
Study: 29973284

Group type: EXPERIMENTAL
Intervention: High-dose JWYH plus usual care
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Low-dose JWYH plus usual care
Number of subjects: 240

Group type: COMPARATOR
Intervention: Placebo plus usual care
Number of subjects: 240
Study: 28482202

Group type: EXPERIMENTAL
Intervention: Right-to-left (RL) group practicing with the dominant right leg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Left-to-right (LR) group practicing with the non-dominant left leg
Number of subjects: 20
Study: 26277174

Group type: EXPERIMENTAL
Intervention: Saunders traction device
Number of subjects: 150

Group type: COMPARATOR
Intervention: HILT laser therapy
Number of subjects: 150
Study: 23910428

Group type: EXPERIMENTAL
Intervention: Hypertension
Number of subjects: 1662
Study: 20936417

Group type: EXPERIMENTAL
Intervention: Vitamin E (400 mg, twice daily)
Number of subjects: 207

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 207
Study: 19003734

Group type: EXPERIMENTAL
Intervention: 50 mg vitamin C supplementation
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: 500 mg vitamin C supplementation
Number of subjects: 244
Study: 17158417

Group type: EXPERIMENTAL
Intervention: Nutrient-enriched formula (EF)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Formula for term infants (TF)
Number of subjects: 0
Study: 14634735

Group type: EXPERIMENTAL
Intervention: Mechanical aiming device
Number of subjects: 50

Group type: COMPARATOR
Intervention: Fluoroscopy based surgical navigation system
Number of subjects: 50
Study: 10888996

Group type: EXPERIMENTAL
Intervention: Power-assisted adenoidectomy (PAA)
Number of subjects: 177

Group type: COMPARATOR
Intervention: Adenoid curette adenoidectomy (ACA)
Number of subjects: 177
Study: 9373742

Group type: EXPERIMENTAL
Intervention: Low level white noise stimulation
Number of subjects: 96

Group type: COMPARATOR
Intervention: Information and relaxation training
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Tinnitus management training (general)
Number of subjects: 96
Study: 8460615

Group type: EXPERIMENTAL
Intervention: Noninvasive nutritional supplementation at 25% of normal energy recommendations for 6 months
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (no nutritional supplementation)
Number of subjects: 16
Study: 3886142

Group type: EXPERIMENTAL
Intervention: Guanfacine (1 mg/day, once daily)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Guanfacine (2.5 mg/day, once daily)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Methyldopa (763 mg/day, twice daily)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Guanfacine (continued therapy for one year)
Number of subjects: 40
Study: 31569012

Group type: EXPERIMENTAL
Intervention: High-intensity interval training (HIIT)
Number of subjects: 441

Group type: COMPARATOR
Intervention: Non-exercise (NON-EX)
Number of subjects: 441
Study: 29628009

Group type: EXPERIMENTAL
Intervention: High dose aprotinin
Number of subjects: 40

Group type: COMPARATOR
Intervention: Lower doses of aprotinin
Number of subjects: 40
Study: 27538896

Group type: EXPERIMENTAL
Intervention: High-intensity interval training (15 bouts of 30 s at 90%-95% of maximal heart rate)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Moderate-intensity continuous training (40 min at 65%-75% of maximal heart rate)
Number of subjects: 44
Study: 26527048

Group type: EXPERIMENTAL
Intervention: Physician-Pharmacist Collaboration Intervention
Number of subjects: 625

Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 625
Study: 22146999

Group type: EXPERIMENTAL
Intervention: Telmisartan
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: High altitude exposure
Number of subjects: 47
Study: 20008640

Group type: EXPERIMENTAL
Intervention: KRAS mutation status
Number of subjects: 3278

Group type: EXPERIMENTAL
Intervention: BRAF mutation status
Number of subjects: 3278
Study: 18517077

Group type: EXPERIMENTAL
Intervention: Oral fexofenadine (180 mg)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Oral diphenhydramine (50 mg)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Intramuscular diphenhydramine (50 mg)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 18
Study: 16043675

Group type: EXPERIMENTAL
Intervention: Testosterone patch 300 microg/d
Number of subjects: 447

Group type: COMPARATOR
Intervention: Testosterone patch 150 microg/d
Number of subjects: 447

Group type: COMPARATOR
Intervention: Testosterone patch 450 microg/d
Number of subjects: 447

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 447
Study: 12427118

Group type: EXPERIMENTAL
Intervention: Recombinant human enzyme, alpha-galactosidase A (r-halalphaGalA), administered IV at 1 mg/kg biweekly for 11 months
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Recombinant human enzyme, alpha-galactosidase A (r-halalphaGalA)
Number of subjects: 58
Study: 10072221

Group type: EXPERIMENTAL
Intervention: Le(a‐b‐) phenotype
Number of subjects: 1620
Study: 8704837

Group type: EXPERIMENTAL
Intervention: Dynamic mattress replacement surface 1
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Dynamic mattress replacement surface 2
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Static foam mattress replacement
Number of subjects: 110

Group type: COMPARATOR
Intervention: All support surfaces
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Braden Scale score
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Braden Scale sensory perception subscale score
Number of subjects: 110
Study: 1685595

Group type: EXPERIMENTAL
Intervention: Education by video film
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Education by card
Number of subjects: 45

Group type: COMPARATOR
Intervention: Positive control (education by video film + additional education in a room)
Number of subjects: 45
Study: 482028

Group type: EXPERIMENTAL
Intervention: Intradimensional oddity shift (CC group)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Extradimensional oddity shift (PC group)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Extradimensional oddity shift (PP group)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Extradimensional oddity shift (CP group)
Number of subjects: 120
Study: 31646969

Group type: EXPERIMENTAL
Intervention: PGB diluted with 0.5 mL mepivacaine 1% and long 19G needle
Number of subjects: 108

Group type: COMPARATOR
Intervention: PGB alone and long 19G needle
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: PGB diluted with 0.5 mL mepivacaine 1% and short 21G needle
Number of subjects: 108

Group type: COMPARATOR
Intervention: PGB alone and short 21G needle
Number of subjects: 108
Study: 28182690

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (DEX)
Number of subjects: 285

Group type: COMPARATOR
Intervention: Control (CTRL)
Number of subjects: 285
Study: 25816805

Group type: EXPERIMENTAL
Intervention: 1.7 g n‐3 PUFA daily for 3 months
Number of subjects: 162

Group type: COMPARATOR
Intervention: Placebo for 3 months
Number of subjects: 162
Study: 23361260

Group type: EXPERIMENTAL
Intervention: Laparoscopic floppy Nissen fundoplication (LNF)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Laparoscopic Toupet fundoplication (LTF)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Both procedures (LNF and LTF)
Number of subjects: 125
Study: 17701133

Group type: EXPERIMENTAL
Intervention: Rebamipide (100 mg for 7 weeks)
Number of subjects: 309

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 309
Study: 15251636

Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy aiming for strict normoglycemia (80 to 110 mg/dL or 4.5 to 6.1 mmol/L) during intensive care
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy
Number of subjects: 0
Study: 11054443

Group type: EXPERIMENTAL
Intervention: Antibiotic regimen A
Number of subjects: 488

Group type: COMPARATOR
Intervention: Antibiotic regimen B
Number of subjects: 488

Group type: EXPERIMENTAL
Intervention: Early discharge strategy based on clinical response
Number of subjects: 488
Study: 9356114

Group type: COMPARATOR
Intervention: O2/NO (Group 2)
Number of subjects: 40

Group type: COMPARATOR
Intervention: O2 (Group 1)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: O2/NO/almitrine (Group 4)
Number of subjects: 40

Group type: COMPARATOR
Intervention: O2 (Group 3)
Number of subjects: 40
Study: 8455332

Group type: EXPERIMENTAL
Intervention: 300 mg OFLX once daily
Number of subjects: 40

Group type: COMPARATOR
Intervention: 600 mg OFLX three times daily
Number of subjects: 40
Study: 3513519

Group type: EXPERIMENTAL
Intervention: Verapamil (120 to 240 mg 2 times a day)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Propranolol (40 to 240 mg 2 times a day)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Both drugs (Verapamil and Propranolol)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 19
Study: 31317662

Group type: EXPERIMENTAL
Intervention: 0.01% bimatoprost
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 0.03% bimatoprost
Number of subjects: 30
Study: 31515458

Group type: EXPERIMENTAL
Intervention: Anti-EGFR antibody treatment (n = 12 class 2, n = 28 class 3)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: First- or second-line anti-EGFR therapy
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Third- or later-line anti-EGFR therapy
Number of subjects: 40
Study: 28095527

Group type: EXPERIMENTAL
Intervention: One dental implant
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Two dental implants
Number of subjects: 36

Group type: COMPARATOR
Intervention: One or two dental implants
Number of subjects: 36
Study: 26831734

Group type: EXPERIMENTAL
Intervention: Real bi‐hemispheric tDCS (cathode/anode: C4/C3)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Uni‐hemispheric tDCS (cathode/anode: Fp3/C3)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Sham bi‐hemispheric tDCS
Number of subjects: 16
Study: 24139233

Group type: EXPERIMENTAL
Intervention: Spinal manipulation (12 sessions)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Spinal manipulation (18 sessions)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Spinal manipulation (0, 6, 12, or 18 sessions)
Number of subjects: 400
Study: 22928389

Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA) 1%
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Ketoprofene (KTP) 1%
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Ketoprofene (KTP) 2%
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study: 19579812

Group type: EXPERIMENTAL
Intervention: Icodextrin-containing dialysis fluid
Number of subjects: 11
Study: 17502825

Group type: EXPERIMENTAL
Intervention: Gas permeable (GP) lenses
Number of subjects: 14

Group type: COMPARATOR
Intervention: Non-GP lenses
Number of subjects: 14
Study: 14728639

Group type: EXPERIMENTAL
Intervention: 17‐beta micronized estradiol
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 12006526

Group type: EXPERIMENTAL
Intervention: Anthracycline-based therapy (HEC)
Number of subjects: 430

Group type: EXPERIMENTAL
Intervention: Anthracycline-based therapy (EC)
Number of subjects: 430

Group type: COMPARATOR
Intervention: Cyclophosphamide, methotrexate, and 5-fluorouracil (CMF)
Number of subjects: 430
Study: 9819447

Group type: EXPERIMENTAL
Intervention: Interferon alfa-2b plus ribavirin (1000 to 1200 mg orally per day for six months)
Number of subjects: 345

Group type: COMPARATOR
Intervention: Interferon alfa-2b alone (placebo)
Number of subjects: 345
Study: 7667050

Group type: EXPERIMENTAL
Intervention: Clarithromycin suspension 15 mg/kg/day divided twice a day
Number of subjects: 260

Group type: COMPARATOR
Intervention: Erythromycin suspension 40 mg/kg/day divided twice or three times a day
Number of subjects: 260
Study: 2468932

Group type: EXPERIMENTAL
Intervention: 10 mg SK&F 86466
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 25 mg SK&F 86466
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 50 mg SK&F 86466
Number of subjects: 8

Group type: COMPARATOR
Intervention: SK&F 86466
Number of subjects: 8
Study: 62834

Group type: EXPERIMENTAL
Intervention: Verbal/visual feedback
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: Specific feedback techniques
Number of subjects: 267

Group type: COMPARATOR
Intervention: Three presentation methods
Number of subjects: 267
Study: 30248280

Group type: EXPERIMENTAL
Intervention: Continuity of midwifery care
Number of subjects: 339

Group type: COMPARATOR
Intervention: General practitioner and midwife visits
Number of subjects: 339
Study: 27692021

Group type: EXPERIMENTAL
Intervention: Behavioural Activation (BA), single session
Number of subjects: 46

Group type: COMPARATOR
Intervention: Waiting list control
Number of subjects: 46
Study: 26035255

Group type: EXPERIMENTAL
Intervention: Elotuzumab plus lenalidomide and dexamethasone
Number of subjects: 646

Group type: COMPARATOR
Intervention: Lenalidomide and dexamethasone (control group)
Number of subjects: 646
Study: 23910791

Group type: EXPERIMENTAL
Intervention: Acceptance of food cravings
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Suppression of food cravings
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (allowed to eat from the food)
Number of subjects: 0
Study: 21288351

Group type: EXPERIMENTAL
Intervention: Sevelamer carbonate (1600 mg with meals for 4 weeks, then randomized to continue for 36 weeks)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo (identical to sevelamer carbonate, for 36 weeks)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Sevelamer carbonate
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 18727661

Group type: EXPERIMENTAL
Intervention: On‐St group (patients on steroids at 15th day after transplantation)
Number of subjects: 148

Group type: COMPARATOR
Intervention: Off‐St group (patients not on steroids at 15th day after transplantation)
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: On‐St group
Number of subjects: 148

Group type: COMPARATOR
Intervention: Off‐St group
Number of subjects: 148
Study: 16452695

Group type: EXPERIMENTAL
Intervention: Assertive Community Treatment
Number of subjects: 198

Group type: COMPARATOR
Intervention: Standard Clinical Case Management
Number of subjects: 198
Study: 15323594

Group type: EXPERIMENTAL
Intervention: Fluoxetine dose increase
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Lithium augmentation of fluoxetine
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Desipramine augmentation of fluoxetine
Number of subjects: 55
Study: 11732814

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide nasal spray (IBNS) 80 microg twice per day (b.i.d.)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 144
Study: 9417265

Group type: EXPERIMENTAL
Intervention: NaCl bolus injection (20 ml)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Individual bolus tracking
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Body mass index, injection flow, and contrast material volume
Number of subjects: 0
Study: 7525120

Group type: COMPARATOR
Intervention: Once daily GH injection (3 IU/m2/24 h in the evening)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Twice daily GH injections (3 IU/m2, two-thirds in the evening and one-third in the morning)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Once daily GH injection
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Twice daily GH injections
Number of subjects: 8
Study: 3116111

Group type: EXPERIMENTAL
Intervention: 500 mg of paracetamol
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: 250 mg of diflunisal
Number of subjects: 77

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: First and second doses of paracetamol
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: First and second doses of diflunisal
Number of subjects: 77
Study: 30355428

Group type: EXPERIMENTAL
Intervention: Zirconia crowns (ZC)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Stainless steel crowns (SSC)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Intact contralateral primary molars (Control)
Number of subjects: 13
Study: 27659879

Group type: EXPERIMENTAL
Intervention: CSL112 (2 g)
Number of subjects: 1200

Group type: EXPERIMENTAL
Intervention: CSL112 (6 g)
Number of subjects: 1200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1200
Study: 24689247

Group type: EXPERIMENTAL
Intervention: Mind-wandering
Number of subjects: 0

Group type: COMPARATOR
Intervention: On-task
Number of subjects: 0
Study: 22535858

Group type: EXPERIMENTAL
Intervention: Botulinum toxin A
Number of subjects: 4136
Study: 20012223

Group type: EXPERIMENTAL
Intervention: Experimental diet rich in animal fat from linseed-fed animals
Number of subjects: 160

Group type: COMPARATOR
Intervention: Control diet with less animal fat and higher PUFA/SFA ratio
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Experimental diet
Number of subjects: 160

Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Both diets
Number of subjects: 160